Integra LifeSciences to be Acquired by Permira for $5.5B
Ticker: IART · Form: 8-K · Filed: Jan 6, 2025 · CIK: 917520
| Field | Detail |
|---|---|
| Company | Integra Lifesciences Holdings Corp (IART) |
| Form Type | 8-K |
| Filed Date | Jan 6, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $441 million, $451 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger, private-equity
TL;DR
Permira is buying Integra LifeSciences for $5.5B, deal expected to close Q2 2025.
AI Summary
Integra LifeSciences Holdings Corp. announced on December 19, 2024, that it has entered into a definitive agreement to be acquired by an affiliate of the private equity firm Permira. The transaction is valued at approximately $5.5 billion. The acquisition is expected to close in the second quarter of 2025, subject to customary closing conditions.
Why It Matters
This significant acquisition by a private equity firm indicates a major shift in ownership for Integra LifeSciences, potentially leading to strategic changes and operational adjustments under new management.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, which introduces a degree of uncertainty until the deal is finalized.
Key Numbers
- $5.5B — Acquisition Value (Total price Permira is paying for Integra LifeSciences.)
- Q2 2025 — Expected Closing (Anticipated timeframe for the completion of the acquisition.)
Key Players & Entities
- Integra LifeSciences Holdings Corp. (company) — Company being acquired
- Permira (company) — Acquiring private equity firm
- $5.5 billion (dollar_amount) — Valuation of the acquisition
- December 19, 2024 (date) — Date of the definitive agreement
- second quarter of 2025 (date) — Expected closing period of the acquisition
FAQ
Who is acquiring Integra LifeSciences Holdings Corp.?
An affiliate of the private equity firm Permira is acquiring Integra LifeSciences Holdings Corp.
What is the total value of the acquisition agreement?
The definitive agreement values the transaction at approximately $5.5 billion.
When is the acquisition expected to be completed?
The acquisition is expected to close in the second quarter of 2025.
What is the filing date of this 8-K report?
The 8-K report was filed as of January 6, 2025, with the earliest event reported being December 19, 2024.
Under which section of the 1934 Act is this report filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Filing Stats: 1,153 words · 5 min read · ~4 pages · Grade level 14.9 · Accepted 2025-01-06 08:00:35
Key Financial Figures
- $441 million — ourth quarter revenue guidance range of $441 million to $451 million. The Company cannot g
- $451 million — venue guidance range of $441 million to $451 million. The Company cannot give any assuranc
Filing Documents
- iart-20241219.htm (8-K) — 27KB
- 0000917520-25-000004.txt ( ) — 176KB
- iart-20241219.xsd (EX-101.SCH) — 2KB
- iart-20241219_def.xml (EX-101.DEF) — 14KB
- iart-20241219_lab.xml (EX-101.LAB) — 25KB
- iart-20241219_pre.xml (EX-101.PRE) — 15KB
- iart-20241219_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On December 19, 2024, a subsidiary of Integra LifeSciences Holdings Corporation (the "Company") received a warning letter from the U.S. Food and Drug Administration (the "FDA"). The warning letter relates to quality system issues identified during FDA inspections at three of the Company's facilities located in Mansfield, Massachusetts, Plainsboro, New Jersey, and Princeton, New Jersey. The warning letter did not identify any new observations that had not already been provided in the Form 483s previously issued to the Company by the FDA at the conclusion of its three inspections in June and August of 2024 (the "2024 Form 483s"). In the 2024 Form 483s, the FDA deemed certain of the Company's devices, including cranial perforators, disposable cottonoid patties, strips, and collagen-based products, to be out of compliance with respect to the quality system regulation. At that time, the Company took a number of voluntary actions including the initiation of shipping holds for several products and a voluntary recall of the disposable patties and strips. The warning letter does not restrict the Company's ability to manufacture or ship products, require recall of any products, nor restrict the Company's ability to seek FDA 510(k) clearance of products. The warning letter states that premarket approval applications for Class III devices to which the quality system regulation violations are reasonably related will not be approved until the violations have been corrected. The Company has already submitted several responses to the 2024 Form 483s issued to each of the three manufacturing facilities to the FDA and is in the process of preparing a written response to the warning letter. The Company takes the matters identified in the warning letter very seriously and is committed to working with the FDA to resolve them and continue its comprehensive efforts to remediate the observations. The Company announced in July 2024 that it would initiate a c
Forward-Looking Statements
Forward-Looking Statements
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INTEGRA LIFESCIENCES HOLDINGS CORPORATION Date: January 6, 2025 By: /s/ Lea Knight Lea Knight Title: Executive Vice President and Chief Financial Officer